Industry Insights

Obsidian Therapeutics: Unlocking Pivotal R&D Answers

At Benchling, we work with scientists across disciplines throughout academia and industry. In the second of our series of customer videos, we share the story of our partnership with Obsidian Therapeutics, a company that is developing next-generation cell and gene therapies with pharmacologic operating systems. We spoke with Vipin Suri, Vice President of Discovery, about Obsidian's journey with Benchling, which started back in 2016. In this video we discuss collaboration, reducing busywork for scientists and unlocking pivotal R&D answers.

2021-05-Obsidian-case-study.png

Join over 200,000 scientists using Benchling to power their biotech R&D

Helix Image